DK3053576T3 - Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk - Google Patents

Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk Download PDF

Info

Publication number
DK3053576T3
DK3053576T3 DK16161922.6T DK16161922T DK3053576T3 DK 3053576 T3 DK3053576 T3 DK 3053576T3 DK 16161922 T DK16161922 T DK 16161922T DK 3053576 T3 DK3053576 T3 DK 3053576T3
Authority
DK
Denmark
Prior art keywords
methyl
ethyl
imidazol
benzyl ester
acid
Prior art date
Application number
DK16161922.6T
Other languages
English (en)
Inventor
Mohammed I Dibas
Ken Chow
John E Donello
Michael E Garst
Daniel W Gil
Liming Wang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3053576(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3053576T3 publication Critical patent/DK3053576T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (3)

1. Sammensætning omfattende en forbindelse med formel I, dens individuelle enantiomerer, dens individuelle diastereoisomerer, dens hydrater, dens solvater, dens krystalformer, dens individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf, til anvendelse i sænkning af intraokulært tryk i et berørt øje af en menneskelig patient med behov for en sådan behandling ved administration af en terapeutisk effektiv mængde af nævnte sammensætning;
Formel i hvor R1 er H eller C1-3 alkyl; R2 er H eller C1-3 alkyl; R3 er H, Ci-10 alkyl, heterocykel eller aryl; og R er Ci-10 alkyl, heterocykel eller aryl, hvor "alkyl" betyder en mættet monovalent alkandel, som har lige eller forgrenede alkandele eller kombinationer deraf, som eventuelt kan substitueres af aminogrupper, arylgrupper, halogener, og et methylen (-CH2-) kan erstattes af carbonyl, -NH-, carboxyl, amid, svovl eller af oxygen, og "heterocykel" betyder en aromatisk eller ikke-aromatisk 5- til 10-leddet monocyklisk eller bicyklisk ring, som indeholder mindst ét heteroatom valgt fra O eller N eller S eller kombinationer deraf, som afbryder den carbocykliske ringstruktur, som eventuelt kan substitueres af C1-6 alkyl, amino, halogen, -O(Ci-e alkyl), -OC(O)(Ci-e alkyl), -C(O)O(Ci-e alkyl), -NHC(O)(Ci-e alkyl), -C(O)NH(Ci-6 alkyl), -S(Ci-e alkyl) grupper, og
"aryl" betyder en organisk del afledt fra et aromatisk carbonhydrid bestående af en monocyklisk eller bicyklisk ring, som indeholder 6-10 kulstofatomer ved fjernelse af et hydrogenatom, såsom phenyl eller naphthyl, som eventuelt kan substitueres af, men ikke begrænset til, Ci-6 alkyl, amino, halogen, -O(Ci-e alkyl), -OC(O)(Ci-e alkyl), - C(O)O(Ci-e alkyl), -NHC(O)(Ci-6 alkyl), -C(O)NH(Ci-6 alkyl), og -S(Ci-e alkyl) grupper.
2-Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzyl ester.
15. Artikel til fremstilling omfattende indpakningsmateriale og et farmaceutisk middel indeholdt i nævnte indpakningsmateriale, hvor det farmaceutiske middel er terapeutisk effektivt til sænkning af intraokulært tryk og hvor indpakningsmaterialet omfatter et mærke, som indikerer, at det farmaceutiske middel kan anvendes til sænkning af intraokulært tryk og hvor nævnte farmaceutiske middel omfatter en effektiv mængde af en forbindelse valgt fra gruppen bestående af: /'so-smørsyre 3-[(S)-l-(l-/'so-butyryl-lH-imidazol-4-yl)-ethyl]-2-methylbenzyl ester; 2,2-Dimethyl-propionsyre 3-((S)-l-[l-(2,2-dimethyl-propionyl)-lA7-imidazol-4-yl]-ethyl}-2-methyl-benzylester; eddikesyre 3-[(S)-l-(l-acetyl-lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(l-benzoyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzyl ester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2-Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eller et farmaceutisk acceptabelt salt deraf.
9. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor sammensætningen yderligere omfatter fra 0,001 til 1 vægtprocent af et konserveringsmiddel.
10. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-9, hvor sammensætningen yderligere omfatter fra 0,01 til 0,5 vægtprocent af et konserveringsmiddel.
11. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-10, hvor sammensætningen yderligere omfatter fra 0,001 til 0,01 vægtprocent af et konserveringsmiddel.
12. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-11, hvor sammensætningen yderligere omfatter fra 0,01 til 1 vægtprocent af et cosolvent.
13. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-12, hvor sammensætningen yderligere omfatter fra 0,01 til 2 vægtprocent af et viskositetsfremmende middel.
14. Artikel til fremstilling omfattende indpakningsmateriale og et farmaceutisk middel indeholdt i nævnte indpakningsmateriale, hvor det farmaceutiske middel er terapeutisk effektivt til sænkning af intraokulært tryk og hvor indpakningsmaterialet omfatter et mærke, som indikerer, at det farmaceutiske middel kan anvendes til sænkning af intraokulært tryk og hvor nævnte farmaceutiske middel omfatter en effektiv mængde af en forbindelse valgt fra gruppen bestående af: /'so-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eddikesyre 3-[(S)-l-(l/-/-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2- Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eller et farmaceutisk acceptabelt salt deraf.
8. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor sammensætningen omfatter 0,05 til 2 vægtprocent, afen forbindelse valgt fra: /'so-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3- Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2- Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eller et farmaceutisk acceptabelt salt deraf; eller hvor sammensætningen omfatter 0,005 til 2 vægtprocent, afen forbindelse valgt fra: /'so-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eddikesyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3- Methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2-Amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eller hvor forbindelsen er valgt fra: /'so-smørsyre 3-[(S)-l-(l-/so-butyryl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-((S)-l-[l-(2,2-dimethyl-propionyl)-lA7-imidazol-4-yl]-ethyl}-2-methyl-benzylester; eddikesyre 3-[(S)-l-(l-acetyl-lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(l-benzoyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3- Methyl-smørsyre 2-methyl-3-{(S)-l-[l-(3-methyl-butyryl)-lH-imidazol- 4- yl]-ethyl}-benzylester; Phenyl-propionsyre 2-methyl-3-{(S)-l-[l-(3-phenyl-propionyl)-lH-imidazol-4-yl]-ethyl}-benzylester; 2-tert-Butoxycarbonylamino-3-methyl-smørsyre 3-{(S)-l-[l-(2-terf·-butoxy carbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-tert-Butoxycarbonylamino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-terf’-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-{(S)-l-[l-(2-f’erf’-butoxycarbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-(2-terf’-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-terf’-Butoxycarbonylamino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og 2-tert-Butoxycarbonylamino-3-phenyl-propionsyre 3-[(S)-l-(lA7-imidazol- 4-yl)-ethyl]-2-methyl-benzylester.
6. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor det berørte øje bevarer et intraokulært tryk på mindre end det intraokulære baselinetryk i mindst otte (8) timer; eller hvor det berørte øje bevarer et intraokulært tryk på mindre end det intraokulære baselinetryk i mindst ti (10) timer; eller hvor det berørte øje bevarer et intraokulært tryk på mindre end det intraokulære baselinetryk i mindst tolv (12) timer.
7. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor sammensætningen omfatter 0,0005 til 5 vægtprocent, afen forbindelse valgt fra: /'so-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
2-Amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-Amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og
2. Sammensætningen til anvendelse ifølge krav 1, hvor forbindelsen er af formel II, dens individuelle diastereoisomerer, dens hydrater, dens solvater, dens krystalformer, dens individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf,
Formel II hvor R1, R2, R3 og R er som defineret i krav 1.
3. Sammensætningen til anvendelse ifølge krav 1, hvor forbindelsen er af formel III, dens individuelle diastereoisomerer, dens hydrater, dens solvater, dens krystalformer, dens individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf,
Formel III hvor R1, R2, R3 og R er som defineret i krav 1.
4. Sammensætningen til anvendelse ifølge krav 2, hvor R1 er C1-3 alkyl, R2 er C1-3 alkyl, R3 er H og R er C1-10 alkyl; eller hvor R1 er methyl, R2 er methyl, R3 er H og R er C1-4 alkyl.
5. Sammensætningen til anvendelse ifølge krav 2, hvor forbindelsen er valgt fra: /'so-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2,2-Dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester;
3- Methyl-smørsyre 2-methyl-3-{(S)-l-[l-(3-methyl-butyryl)-lH-imidazol- 4- yl]-ethyl}-benzylester; Phenyl-propionsyre 2-methyl-3-{(S)-l-[l-(3-phenyl-propionyl)-lH-imidazol-4-yl]-ethyl}-benzylester; 2-terf’-Butoxycarbonylamino-3-methyl-smørsyre 3-{(S)-l-[l-(2-terf·-butoxy carbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-ίβΓί·-ΒυίοχγεθΓ0οηγΙθΓηϊηο-3-Γη6ίήγΙ-5Γη0Γ5γΓ6 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-terf’-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-{(S)-l-[l-(2-f’erf’-butoxycarbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl-benzylester; 2-(2-terf’-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-terf’-Butoxycarbonylamino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lA7-imidazol-4-yl)-ethyl]-2-methyl-benzylester; og 2-tert-Butoxycarbonylamino-3-phenyl-propionsyre 3-[(S)-l-(lA7-imidazol- 4-yl)-ethyl]-2-methyl-benzylester.
DK16161922.6T 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk DK3053576T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
EP11760962.8A EP2616068B1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
DK3053576T3 true DK3053576T3 (da) 2018-08-20

Family

ID=44675870

Family Applications (9)

Application Number Title Priority Date Filing Date
DK19194325.7T DK3636263T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK16161920.0T DK3050563T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande
DK16161922.6T DK3053576T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760963.6T DK2616069T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
DK16161921.8T DK3078376T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK18157147.2T DK3338777T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161923T DK3050564T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK18160174.1T DK3348264T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760962.8T DK2616068T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK19194325.7T DK3636263T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK16161920.0T DK3050563T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande

Family Applications After (6)

Application Number Title Priority Date Filing Date
DK11760963.6T DK2616069T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
DK16161921.8T DK3078376T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK18157147.2T DK3338777T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161923T DK3050564T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK18160174.1T DK3348264T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760962.8T DK2616068T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk

Country Status (29)

Country Link
US (9) US8492422B2 (da)
EP (13) EP3698789A1 (da)
JP (4) JP2013537236A (da)
KR (7) KR101952457B1 (da)
CN (5) CN103200941B (da)
AR (4) AR083020A1 (da)
AU (4) AU2011301847B2 (da)
BR (4) BR112013006362A2 (da)
CA (8) CA2812197C (da)
CL (4) CL2013000736A1 (da)
CY (3) CY1121024T1 (da)
DK (9) DK3636263T3 (da)
ES (10) ES2788051T3 (da)
HK (5) HK1185541A1 (da)
HU (5) HUE047476T2 (da)
IL (4) IL225282A0 (da)
MX (4) MX2013003002A (da)
MY (4) MY168763A (da)
NZ (1) NZ608751A (da)
PL (7) PL3348264T3 (da)
PT (7) PT3050564T (da)
RU (4) RU2013116403A (da)
SG (4) SG188571A1 (da)
SI (5) SI3050564T1 (da)
TR (1) TR201909249T4 (da)
TW (4) TW201240662A (da)
UA (1) UA112973C2 (da)
WO (4) WO2012037490A1 (da)
ZA (4) ZA201302194B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566703B1 (en) 2009-02-13 2021-04-07 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
WO2013016073A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
EP4322943A1 (en) * 2021-04-16 2024-02-21 ADS Therapeutics LLC Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
KR20060052809A (ko) * 2003-07-14 2006-05-19 코닌클리케 필립스 일렉트로닉스 엔.브이. 프로젝션 디바이스
BRPI0414277A (pt) 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2481412B1 (en) 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
AU2005290075A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2010091209A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
EP3566703B1 (en) * 2009-02-13 2021-04-07 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Also Published As

Publication number Publication date
DK3078376T3 (da) 2019-06-24
CN105412092A (zh) 2016-03-23
IL225278A0 (en) 2013-06-27
EP3053576B1 (en) 2018-05-16
CA2812197C (en) 2024-01-02
HK1185538A1 (zh) 2014-02-21
CN103200941B (zh) 2015-12-16
JP6045495B2 (ja) 2016-12-14
PL2616069T3 (pl) 2017-04-28
US20160354346A1 (en) 2016-12-08
EP2616066A1 (en) 2013-07-24
JP2013541527A (ja) 2013-11-14
PL2616068T3 (pl) 2016-11-30
CN105412092B (zh) 2020-11-17
MX2013003004A (es) 2013-06-28
TW201240661A (en) 2012-10-16
EP3348264B1 (en) 2020-01-01
AU2011301856C1 (en) 2016-09-08
DK2616069T3 (da) 2016-12-19
US20150148394A1 (en) 2015-05-28
CL2013000734A1 (es) 2013-11-08
KR20140003407A (ko) 2014-01-09
IL225278A (en) 2015-11-30
WO2012037490A1 (en) 2012-03-22
CA2811559A1 (en) 2012-03-22
US8501796B2 (en) 2013-08-06
KR20200044147A (ko) 2020-04-28
ES2593612T3 (es) 2016-12-12
KR101952457B1 (ko) 2019-02-26
WO2012037484A1 (en) 2012-03-22
CL2013000736A1 (es) 2013-07-12
AR083019A1 (es) 2013-01-23
US20120142746A1 (en) 2012-06-07
ES2760920T3 (es) 2020-05-18
EP3338777A1 (en) 2018-06-27
ES2684055T3 (es) 2018-10-01
ES2788051T3 (es) 2020-10-20
AR083018A1 (es) 2013-01-23
US8853251B2 (en) 2014-10-07
PT3050563T (pt) 2018-10-01
KR102139905B1 (ko) 2020-07-31
KR102354097B1 (ko) 2022-01-20
AU2011301847A1 (en) 2013-05-02
EP3050564B1 (en) 2019-09-04
SG188572A1 (en) 2013-04-30
PT2616068T (pt) 2016-09-13
CA3079450A1 (en) 2012-03-22
SG188570A1 (en) 2013-04-30
CN103200941A (zh) 2013-07-10
MY191369A (en) 2022-06-20
RU2612351C2 (ru) 2017-03-07
CA3116249A1 (en) 2012-03-22
HK1257416A1 (zh) 2019-10-18
JP6073229B2 (ja) 2017-02-01
KR102104760B1 (ko) 2020-04-27
PT3053576T (pt) 2018-10-08
CN103200942A (zh) 2013-07-10
CA2812195A1 (en) 2012-03-22
CL2013000735A1 (es) 2013-11-29
EP2616068A1 (en) 2013-07-24
EP3050564A1 (en) 2016-08-03
JP2013537237A (ja) 2013-09-30
HUE039090T2 (hu) 2018-12-28
KR20190022895A (ko) 2019-03-06
KR101840500B1 (ko) 2018-03-20
KR101840501B1 (ko) 2018-05-04
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
US8653123B2 (en) 2014-02-18
AU2011301932B2 (en) 2016-02-25
DK3050563T3 (da) 2018-08-13
TW201240662A (en) 2012-10-16
WO2012037453A1 (en) 2012-03-22
MX2013003009A (es) 2013-06-28
US20120149746A1 (en) 2012-06-14
KR20140005154A (ko) 2014-01-14
ZA201302288B (en) 2013-11-27
DK3338777T3 (da) 2020-04-20
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
CA3122745A1 (en) 2012-03-22
ES2607084T3 (es) 2017-03-29
AU2011301932A1 (en) 2013-05-02
EP3636263B1 (en) 2021-11-03
TW201305116A (zh) 2013-02-01
SI3338777T1 (sl) 2020-08-31
AU2011301932C1 (en) 2016-09-01
EP3078376B1 (en) 2019-03-27
HK1185541A1 (zh) 2014-02-21
HK1185539A1 (zh) 2014-02-21
CY1122958T1 (el) 2021-10-29
ZA201302194B (en) 2013-11-27
RU2013116403A (ru) 2014-10-27
EP2616066B1 (en) 2016-07-13
RU2013116405A (ru) 2014-10-27
CA2812191A1 (en) 2012-03-22
EP3078376A1 (en) 2016-10-12
US8492557B2 (en) 2013-07-23
EP3659600A1 (en) 2020-06-03
IL225280A0 (en) 2013-06-27
SI3050564T1 (sl) 2020-02-28
SI3348264T1 (sl) 2020-07-31
DK3050564T3 (da) 2019-11-25
EP2616067A1 (en) 2013-07-24
MY168763A (en) 2018-12-04
IL225282A0 (en) 2013-06-27
NZ608751A (en) 2015-04-24
CL2013000733A1 (es) 2013-08-23
KR20200091507A (ko) 2020-07-30
AU2011301847B2 (en) 2016-02-11
PL3338777T3 (pl) 2020-07-13
MY161607A (en) 2017-04-28
HUE049573T2 (hu) 2020-10-28
EP2616069B1 (en) 2016-11-16
TWI591058B (zh) 2017-07-11
EP3338777B1 (en) 2020-02-05
PT3348264T (pt) 2020-04-02
ES2904479T3 (es) 2022-04-05
PL3348264T3 (pl) 2020-08-24
MX2013003002A (es) 2013-06-28
US20130296394A1 (en) 2013-11-07
MY173846A (en) 2020-02-24
AU2011301856A1 (en) 2013-05-02
PL3050563T3 (pl) 2018-12-31
SI3053576T1 (sl) 2018-11-30
CN103209694A (zh) 2013-07-17
KR20130114140A (ko) 2013-10-16
UA112973C2 (uk) 2016-11-25
EP3636263A1 (en) 2020-04-15
US20120122945A1 (en) 2012-05-17
AU2011301901B2 (en) 2016-02-11
CA3077732A1 (en) 2012-03-22
ES2737230T3 (es) 2020-01-10
RU2013116541A (ru) 2014-10-27
PT3338777T (pt) 2020-05-06
ZA201302193B (en) 2013-11-27
AU2011301901A1 (en) 2013-05-02
CA2812197A1 (en) 2012-03-22
DK3636263T3 (da) 2022-01-10
US20140057958A1 (en) 2014-02-27
EP3050563B1 (en) 2018-05-09
EP2616067B1 (en) 2016-05-18
ES2613509T3 (es) 2017-05-24
SG188571A1 (en) 2013-04-30
SG188573A1 (en) 2013-04-30
HUE048725T2 (hu) 2020-09-28
ZA201302291B (en) 2013-11-27
EP3348264A1 (en) 2018-07-18
DK2616068T3 (da) 2016-08-29
TR201909249T4 (tr) 2019-07-22
ES2687420T3 (es) 2018-10-25
AR083020A1 (es) 2013-01-23
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
HUE038698T2 (hu) 2018-11-28
HUE047476T2 (hu) 2020-04-28
US8492422B2 (en) 2013-07-23
SI3050563T1 (sl) 2018-10-30
BR112013006320B1 (pt) 2022-08-30
ES2781681T3 (es) 2020-09-04
MX2013003008A (es) 2013-06-28
WO2012037499A1 (en) 2012-03-22
PT2616069T (pt) 2016-12-06
DK3348264T3 (da) 2020-03-23
JP2013537236A (ja) 2013-09-30
BR112013006355A2 (pt) 2016-06-28
CY1122809T1 (el) 2021-05-05
TW201305117A (zh) 2013-02-01
BR112013006352A2 (pt) 2016-06-28
US20130289088A1 (en) 2013-10-31
EP3050563A1 (en) 2016-08-03
CY1121024T1 (el) 2019-12-11
US20120136036A1 (en) 2012-05-31
PL3053576T3 (pl) 2018-11-30
EP3698789A1 (en) 2020-08-26
PL3050564T3 (pl) 2020-06-01
JP2013540749A (ja) 2013-11-07
PT3050564T (pt) 2019-12-11
BR112013006320A2 (pt) 2016-06-21
CA2812191C (en) 2021-04-13
IL225281A0 (en) 2013-06-27
EP3053576A1 (en) 2016-08-10
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28

Similar Documents

Publication Publication Date Title
DK3053576T3 (da) Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
AU2011301856B2 (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol